Ceapro Inc. Reports Third Quarter 2014 Financial Results

- Company delivers strongest quarterly financial performance in its history - - Further increased revenue generation and market expansion expected in 2015 -

EDMONTON, ALBERTA--( Nov 14, 2014) - Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the "Company"), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the third quarter and nine-months ended September 30, 2014.

Third Quarter 2014 Financial Highlights

• Total sales of $2,445,000 for the third quarter 2014, an increase of 22% over third quarter 2013 and the highest quarterly revenue to date.
• Total sales of $6,831,000 for the nine-month period ended September 30, 2014, an increase of 36% over the same period in 2013. Sales for the first nine-month of 2014 surpassed sales of the previous full 12 month record year of 2013.
• Third quarter 2014 income from operations of $731,000, an increase of $533,000 from third quarter 2013.
• Net profit for third quarter 2014 of $690,000 versus $123,000 in third quarter 2013.